OakChart

Wave Life Sciences Inc

WVEHealthcare·Biotechnology·USA·Small·NASD·Nov 11 • 3:59 PM ET

3.42+0.01 (0.29%)
2026-11-12 00:27 CET
Market cap
672.55 USD m
Revenue, TTM
70.92 USD m
Net income, TTM
-210.53 USD m
Free cash flow, TTM
-206.48 USD m
EPS diluted, TTM
-1.07
P/E
-
Compare

Price

WVE against its 20, 50 and 200-day averages
2050200beatmiss
4.006.008.0010.004.0M8.1MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26WVEclose 3.4220-day 3.4050-day 3.80200-day 7.023.4252w low

84.3% under the 52-week high of 21.73 on 9 Dec 2025. 52-week low 3.04 on 14 Oct 2026. Last 15 sessions, 23.7% high to low

Volume 0.51× normal · the line is the 50-bar volume average

Profile

WVE
52-week range, 2% of the way up
3.0421.73

Wave Life Sciences, Inc. is a clinical-stage biotechnology company, which focuses on developing its proprietary RNA medicines platform and PRISM. It develops and commercializes a pipeline of RNA medicines across a variety of therapeutic areas. The company was founded by Gregory L. Verdine and Takeshi Wada on July 23, 2012 and is headquartered in Cambridge, MA.

IndexRUT
Employees317
IPONov 11, 2015
Beta-1.42
ATR, 14d0.23
Rel volume0.51
Short float12.49%
Insider own16.18%
Inst own97.63%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap674.52M
Enterprise Value287.04M
Income-210.53M
Sales70.92M
Book/sh2.04
Cash/sh2.18
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees317
IPONov 11, 2015

Ratios

P/E-
Forward P/E-
PEG-
P/S9.51
P/B1.68
P/C1.57
P/FCF-
EV/EBITDA-
EV/Sales4.05
Quick Ratio8.38
Current Ratio8.38
Debt/Eq0.11
LT Debt/Eq0.10
Option/ShortYes / Yes

Earnings

EPS (ttm)-1.07
EPS next Y-1.27
EPS next Q-0.33
EPS this Y8.50%
EPS next Y-14.95%
EPS next 5Y-0.92%
EPS past 3/5Y16.10% 20.52%
Sales past 3/5Y127.08% 16.31%
EPS Y/Y TTM-45.17%
Sales Y/Y TTM-35.07%
EPS Q/Q5.55%
Sales Q/Q72.95%
EarningsOct 27 BMO
EPS/Sales Surpr.8.81% 191.60%

Ownership

Insider Own16.18%
Insider Trans-0.08%
Inst Own97.63%
Inst Trans0.06%
ROA-56.19%
ROE-78.80%
ROIC-47.76%
Gross Margin86.99%
Oper. Margin-320.94%
Profit Margin-296.86%
SMA200.67%
SMA50-9.96%
SMA200-51.25%
Trades-

Technical

Shs Outstand197.21M
Shs Float165.32M
Short Float12.49%
Short Ratio6.19
Short Interest20.65M
52W High21.73 -84.26%
52W Low3.04 12.50%
Volatility8.36% 6.72%
ATR (14)0.23
RSI (14)45.72
Beta-1.42
Rel Volume0.51
Avg Volume3.33M
Volume1,704,486

Performance

Perf Week-5.52%
Perf Month8.92%
Perf Quarter-34.23%
Perf Half Y-51.07%
Perf YTD-79.88%
Perf Year-52.89%
Perf 3Y-34.86%
Perf 5Y-27.85%
Perf 10Y-90.63%
Recom1.15
Target Price18.07
Prev Close3.41
Price3.42
Change %0.29%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Oct 16, 2026InitiatedWWilliam BlairOutperform
Oct 15, 2026InitiatedUUBSBuy$11+221.6%
Oct 01, 2026InitiatedLLadenburg ThalmannBuy$10+192.4%
Sep 23, 2026ResumedJJP MorganNeutral
Apr 29, 2026ResumedTTruistBuy$15+338.6%
Feb 05, 2026InitiatedBBofA SecuritiesBuy$38+1,011.1%
Dec 12, 2025ReiteratedWWedbushOutperform$20 → $33+864.9%
Dec 09, 2025UpgradeRRBC Capital MktsSector Perform → Outperform$27+689.5%
Oct 20, 2025InitiatedWWells FargoOverweight$18+426.3%
Aug 04, 2025InitiatedCCanaccord GenuityBuy$19+455.6%

Peers

Mkt cap
TickerCompanyMkt cap
IONSIonis Pharmaceuticals Inc4.72B
BEAMBeam Therapeutics Inc2.67B
ARWRArrowhead Pharmaceuticals Inc6.97B
DYNDyne Therapeutics Inc3.37B
ALNYAlnylam Pharmaceuticals Inc21.41B
SRPTSarepta Therapeutics Inc1.79B
SLNSilence Therapeutics Plc ADR1.23B
TRDAEntrada Therapeutics Inc212.98M
ADRXADARx Pharmaceuticals Inc1.47B
NTLAIntellia Therapeutics Inc1.60B

Insider trading

latest 14 of 50
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Wagner Heidi LDirectorAug 11 '26Option Exercise5.977,00041,79051,930Aug 13 09:00 PM
Wagner Heidi LDirectorAug 11 '26Sale6.017,00042,07044,930Aug 13 09:00 PM
Rawcliffe AdrianDirectorAug 12 '26Sale5.2912,70067,1830Aug 13 09:00 PM
TAKANASHI KENDirectorAug 11 '26Sale6.013,86423,22320,079Aug 13 09:00 PM
Tan Aik NaDirectorAug 11 '26Sale6.014322,59624,968Aug 13 09:00 PM
ADRIAN G RAWCLIFFEDirectorAug 12 '26Proposed Sale5.0412,70064,072Aug 12 04:32 PM
HEIDI L WAGNERDirectorAug 11 '26Proposed Sale6.077,00042,490Aug 11 04:30 PM
RA CAPITAL MANAGEMENT, L.P.DirectorMar 26 '26Buy6.085,305,78232,265,43123,508,791Mar 30 08:30 PM
RA CAPITAL MANAGEMENT, L.P.DirectorMar 27 '26Buy6.432,495,62316,046,85626,004,414Mar 30 08:30 PM
RA CAPITAL MANAGEMENT, L.P.DirectorMar 30 '26Buy6.50971,0916,312,09226,975,505Mar 30 08:30 PM
Francis ChrisSee RemarksFeb 26 '26Option Exercise4.2833,194141,92079,767Feb 27 09:00 PM
Francis ChrisSee RemarksFeb 26 '26Sale15.0533,194499,59361,867Feb 27 09:00 PM
Moran KyleChief Financial OfficerFeb 09 '26Sale13.453,58848,259134,385Feb 11 09:03 PM
BOLNO PAULPresident and CEOFeb 09 '26Sale13.4510,480140,956275,520Feb 11 09:02 PM

Held by

AUM
TickerCompanyAUM
IWMiShares Russell 2000 Index FundAUM: 77.38B
XPHState Street SPDR S&P Pharmaceuticals ETFAUM: 516.35M
VXFVanguard Extended Market Index ETFAUM: 30.47B
IBBiShares Biotechnology ETFAUM: 11.36B
IWNiShares Russell 2000 Value ETFAUM: 14.10B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
SCHASchwab U.S. Small-Cap ETFAUM: 22.25B
DFASU.S. Small Cap Portfolio-ETF Class SharesAUM: 15.51B
IHEiShares U.S. Pharmaceuticals ETFAUM: 1.72B
FESMFidelity Enhanced Small Cap Core ETFAUM: 6.82B

News

latest 14 of 100
  • Wave Life Sciences to Present at Jefferies Global Healthcare Conference in London (GlobeNewswire)
  • Wave Life Sciences Beats On A GSK Milestone, But Shares Near Lows Put The Focus On WVE-007 Data Timing And Rising Spending (Earnings Whispers) +7.48%
  • Wave Life Sciences: Q3 Earnings Snapshot (Associated Press)
  • Wave Life Sciences Reports Third Quarter 2026 Financial Results and Provides Business Update (GlobeNewswire)
  • Wave Life Sciences Third Quarter 2026 Financial Results Scheduled for October 27, 2026 (GlobeNewswire) +7.89%
  • Wave Life Sciences to Host Virtual Research Day on Wednesday, November 4, 2026 (GlobeNewswire)
  • Wave Life Sciences to Present at Chardan's 10th Annual Healthcare Conference (GlobeNewswire)
  • Lilly, Foghorn part ways; Waves FDA-approved plans (BioPharma Dive)
  • Wave Life Sciences Announces FDA Feedback Supports Registrational Pathway for WVE-006 (RNA Editing) in AATD (GlobeNewswire)
  • Wave Life Sciences Announces GSK's Selection of siRNA program to Transition to GSK for Further Development (GlobeNewswire)
  • Wave Life Sciences Initiates Phase 2a Combination Trial of WVE-007 (GalNAc-siRNA) with Tirzepatide for Obesity (GlobeNewswire) -9.20%
  • Wave Life Sciences Announces Appointment of Dr. Monika Vnuk as Chief Business Officer (GlobeNewswire)
  • These beaten-down stocks could bounce back in January, if history is any guide (MarketWatch)
  • Wave Life Sciences to Present at Cantor 2026 Global Healthcare Conference (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-10-27-0.300-0.329-0.30113.164.5119
2026Q22026-07-30-0.340-0.300-0.3402.277.4516
2026Q12026-04-28-0.130-0.324-0.13038.258.4515
2025Q42026-02-26-0.300-0.273-0.29517.2416.0615
2025Q32025-11-10-0.320-0.304-0.3217.6112.6312
2025Q22025-07-30-0.310-0.277-0.3088.7013.2014
2025Q12025-05-08-0.290-0.260-0.2889.1811.9210
2024Q42025-03-040.180-0.1790.17083.7528.679
2024Q32024-11-12-0.470-0.283-0.466-7.6816.619
2024Q22024-08-08-0.250-0.207-0.25419.6919.456
2024Q12024-05-09-0.240-0.186-0.24412.5425.005
2023Q42024-03-06-0.150-0.227-0.14829.0619.866
2023Q32023-11-090.070-0.1780.06549.2123.436
2023Q22023-08-03-0.200-0.331-0.20022.117.947
2023Q12023-05-03-0.270-0.040-0.26912.9332.335
2022Q42023-03-22-0.470-0.410-0.4651.247.066

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-5.720-5.454-5.71815.9818.94
2020FY-3.820-3.753-3.82220.0820.48
2021FY-2.360-2.223-2.35940.9652.67
2022FY-2.050-2.012-2.0523.659.40
2023FY-0.540-0.618-0.542113.31103.99
2024FY-0.700-1.137-0.702108.354.07
2025FY-1.210-1.192-1.20342.7341.01
2026FY--1.107--62.85
2027FY--1.273--38.43
2028FY--1.244--54.34
2029FY--1.081--136.56
2030FY--0.320--361.74

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-0817929.630.0022.00
2026Q4S2026-11-0718929.650.0022.00
2026Q4S2026-11-0420929.700.0022.00
2026Q4S2026-11-03209110.350.0023.46
2026Q4S2026-10-28209110.350.0023.46
2026Q4S2026-10-2720819.870.0023.46
2026Q4S2026-10-2019005.960.0023.46
2026Q4S2026-10-1419015.960.0023.46
2026Q4S2026-10-1318116.160.0023.46
2026Q4S2026-09-3017256.230.0023.46
2026Q4S2026-09-2116255.750.0023.46
2026Q4S2026-09-1815256.130.0023.46
2026Q4S2026-08-2315266.130.0023.46
2026Q4S2026-08-0616265.750.0023.46

Estimate history

EPS, annual-3.846-5.062-5.718-3.822-2.359-2.052-0.542-0.702-1.212-1.0686
Period201720182019202020212022202320242025TTM
EPS, quarterly-0.4660.17-0.288-0.308-0.321-0.295-0.13-0.34-0.303
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual3.89314.41415.98320.07740.9643.649113.305108.30242.72770.92
Period201720182019202020212022202320242025TTM
Sales, quarterly-7.67683.7489.1758.6997.60817.24538.2462.27213.158
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual27.82929.47234.34148.77959.84186.925119.162153.037187.66197.214
Period201720182019202020212022202320242025MRQ
Shares, quarterly148.393153.037154.093155.673160.288187.66192.338193.278197.214
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue70.9242.73108.30113.313.6540.9620.0815.9814.41
Cost of Goods Sold Incl. D&A9.238.858.669.2110.11----
Gross Profit61.7033.8899.64104.10-6.46----
Selling, General and Administrative Excl. Other289.31249.26210.04172.10156.26158.15163.47215.10168.36
Research and Development205.39182.78159.68130.01115.86121.88130.94175.43134.43
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-227.61-215.38-110.40-68.00-162.72-127.02-153.38-208.32-159.52
Interest Expense0.000.000.000.000.000.000.02--
Unusual Expense-0.000.000.000.000.000.00--
Net Income Before Taxes-210.53-204.38-97.01-58.19-161.14-122.45-150.75-193.64-146.58
Income Taxes0.000.000.00-0.680.68-0.20-0.840.000.07
Consolidated Net Income-210.53-204.38-97.01-57.51-161.82-122.25-149.91-193.64-146.65
Net Income From Continuing Operations-210.53-204.38-97.01-57.51-161.82-122.25-149.91-193.64-146.65
Net Income-210.53-204.38-97.01-57.51-161.82-122.25-149.91-193.64-146.65
EPS (Recurring)-1.03-1.21-0.70-0.54-2.05-2.36-3.82-5.72-5.06
EPS (Basic, Before Extraordinaries)-1.07-1.21-0.70-0.54-2.05-2.36-3.82-5.72-5.06
EPS (Diluted)-1.07-1.21-0.70-0.54-2.05-2.36-3.82-5.72-5.06
EBITDA-218.39-206.53-101.74-58.79-152.61-117.18-143.39-199.12-153.94
Non-Operating Income (Expense)17.0811.0113.409.811.584.572.6414.6512.92
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense56.3424.9713.147.7413.5813.6211.2915.4112.32
Price To Sales Ratio10.6567.1015.794.73151.273.9715.3816.9884.50
Gross Margin86.9979.2892.0091.88-177.17----
Operating Margin-320.94-504.09-101.94-60.01-4,459.30-310.07-763.94-1,303.37-1,106.72
Net Margin-296.86-478.33-89.57-50.76-4,434.72-298.42-746.68-1,211.52-1,017.43
Shares Outstanding197.21187.66153.04119.1686.9259.8448.7834.3429.47
Market Capitalization672.55672.551,886.67601.01608.37115.33289.05274.831,238.67

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue13.162.2738.2517.257.618.709.1883.75
Cost of Goods Sold Incl. D&A2.292.372.312.262.232.202.162.16
Gross Profit10.87-0.1035.9414.985.386.507.0181.59
Selling, General and Administrative Excl. Other76.9273.7167.2471.4561.7359.2656.8258.63
Research and Development53.8451.2947.4452.8145.8743.4740.6244.65
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-66.05-73.80-31.30-56.47-56.35-52.76-49.8022.97
Interest Expense0.000.000.000.000.000.000.000.00
Unusual Expense-0.000.000.000.000.000.000.00
Net Income Before Taxes-61.91-69.36-26.09-53.18-53.85-50.47-46.8829.25
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-61.91-69.36-26.09-53.18-53.85-50.47-46.8829.25
Net Income From Continuing Operations-61.91-69.36-26.09-53.18-53.85-50.47-46.8829.25
Net Income-61.91-69.36-26.09-53.18-53.85-50.47-46.8829.25
EPS (Recurring)-0.30-0.34-0.13-0.30-0.32-0.31-0.290.17
EPS (Basic, Before Extraordinaries)-0.30-0.34-0.13-0.30-0.32-0.31-0.290.18
EPS (Diluted)-0.30-0.34-0.13-0.30-0.32-0.31-0.290.17
EBITDA-63.76-71.43-28.99-54.20-54.12-50.56-47.6425.12
Non-Operating Income (Expense)4.144.455.213.292.502.292.936.29
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense30.869.069.067.356.476.204.953.24
Price To Sales Ratio10.6518.1320.2171.6811.2411.3512.5119.68
Gross Margin82.60-4.2793.9786.8870.6974.7676.4197.43
Operating Margin-501.95-3,248.33-81.83-327.44-740.71-606.49-542.8227.42
Net Margin-470.53-3,052.60-68.21-308.37-707.83-580.17-510.9334.93
Shares Outstanding197.21193.28192.34187.66160.29155.67154.09153.04
Market Capitalization672.551,117.861,364.853,110.951,164.901,011.161,240.171,886.67

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments602.07302.08200.3588.50150.56184.50147.16174.82142.50
Short Term Receivables1.281.4221.090.000.0030.0020.0010.001.00
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets11.4716.8913.9410.0412.0015.5418.3217.456.99
Total Current Assets614.81320.39235.3798.54162.56230.04185.48202.27150.49
Net Property, Plant & Equipment19.8628.0035.7244.1340.6445.4354.4739.9327.33
Total Investments and Advances3.813.763.703.663.653.653.653.623.61
Long-Term Note Receivable-----0.0030.0050.000.00
Intangible Assets--------0.00
Other Assets0.020.060.160.060.150.1210.660.110.41
Total Assets638.50352.21274.95146.39207.01279.24284.25295.94181.84
Short Term Debt Incl. Current Port. of LT Debt8.367.646.715.504.963.713.240.000.02
Accounts Payable15.7016.2612.8416.917.2813.799.0713.097.60
Other Current Liabilities71.0087.05166.8949.1151.96103.53105.84116.9510.58
Total Current Liabilities95.06110.95186.4471.5264.20121.04118.15130.0418.19
Long Term Debt9.4017.7725.4032.1224.9525.5929.300.000.00
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Other Liabilities7.806.1015.6079.9677.4841.9565.1984.6816.17
Total Liabilities112.27134.82227.44183.60166.63188.59212.64214.7234.36
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value7.877.877.877.877.877.877.877.877.87
Common Equity518.36209.5139.63-45.0932.5082.7863.7373.35139.61
Total Shareholders Equity526.23217.3947.50-37.2240.3790.6571.6181.22147.48
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity526.23217.3947.50-37.2240.3790.6571.6181.22147.48
Total Liabilities & Stockholders Equity638.50352.21274.95146.39207.01279.24284.25295.94181.84
Book Value Per Share2.761.370.33-0.520.541.701.862.495.02
Tangible Book Value Per Share2.761.370.33-0.520.541.701.862.495.02
Full-Time Employees317288268252238220301250168
Price to Book Ratio1.6712.96-12.35-134.515.784.644.3216.895.88
Return on Assets-41.26-30.94-27.30-91.58-50.28-53.21-66.75-61.39-58.84
Return on Equity-54.97-73.24-1,118.17-10,258.19-186.60-184.78-253.41-128.13-70.28
Return on Invested Capital-38.16-41.25-78.88--187.13-128.96-191.89-180.56-69.15
Quick Ratio6.472.891.261.382.531.901.571.568.27
Current Ratio6.472.891.261.382.531.901.571.568.27

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-208.84-204.38-97.01-57.51-161.82-122.25-149.91-193.64-146.65
Depreciation9.158.858.669.2110.119.849.989.205.58
Other Funds (Non Cash)36.6424.9713.149.8017.2116.4114.3019.5115.82
Funds from Operations-163.05-170.55-75.20-38.51-134.50-96.00-125.63-164.93-125.25
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-42.10-16.94-75.8219.086.727.019.65-23.30102.39
Cash from Operating Activities-205.15-187.49-151.03-19.43-127.78-88.99-115.98-188.23-22.86
Capital Expenditures-1.33-0.72-0.94-1.12-1.36-0.56-1.34-3.92-9.94
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00-
Sale of Fixed Assets and Businesses0.000.000.000.000.110.000.000.00-
Purchase or Sale of Investments-236.160.000.000.000.000.000.000.000.00
Purchase of Investments-236.160.000.000.00-75.040.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.0075.040.000.000.000.00
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources3.080.000.000.000.000.000.000.000.00
Cash from Investing Activities-234.40-0.72-0.94-1.12-1.26-0.56-1.34-3.92-9.94
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock445.92488.24253.89132.5367.1955.83154.37164.4065.11
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock445.92488.24253.89132.5367.1955.83154.37164.4065.11
Proceedsfrom Stock Options432.85472.49250.25131.2866.5955.58153.63161.7960.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.000.000.00-0.02
Change in Long Term Debt0.000.000.000.000.000.000.000.00-0.02
Issuance of Long Term Debt0.000.000.000.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.000.000.00-0.02
Net Financing Active Other Cash Flow0.000.000.000.000.000.000.170.000.00
Other Financing Activities Uses0.000.000.000.000.000.000.000.000.00
Cash from Financing Activities445.92488.24253.89132.5367.1955.83154.54164.4065.09
Exchange Rate Effect-0.070.01-0.14-0.10-0.21-0.210.120.110.04
Net Change in Cash6.30300.04101.79111.89-62.06-33.9337.34-27.6432.33
Free Cash Flow-206.48-188.21-151.96-20.55-129.14-89.55-117.32-192.15-32.80
Preferred Dividends (Cash Flow)-0.000.000.000.00----
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments430.75490.60544.59602.07196.22208.48
Short Term Receivables12.000.890.001.2810.001.62
Inventories0.000.000.000.000.000.00
Other Current Assets15.8816.0216.6811.479.2713.46
Total Current Assets458.63507.51561.27614.81215.49223.56
Net Property, Plant & Equipment44.3346.3318.0719.8622.0724.29
Total Investments and Advances4.083.813.813.813.803.78
Other Assets0.900.670.390.020.020.73
Total Assets507.93558.32583.54638.50241.38252.35
Short Term Debt Incl. Current Port. of LT Debt4.383.518.338.368.398.14
Accounts Payable19.3020.3619.0615.7014.4914.66
Other Current Liabilities31.0926.9522.4471.0063.0164.61
Total Current Liabilities54.7650.8149.8395.0685.9087.41
Long Term Debt38.9040.087.399.4011.3813.57
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities12.3413.9014.607.8011.684.23
Total Liabilities105.99104.8071.81112.27108.95105.22
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.007.877.877.87
Common Equity401.94453.52511.73518.36124.55139.27
Total Shareholders Equity401.94453.52511.73526.23132.42147.14
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity401.94453.52511.73526.23132.42147.14
Total Liabilities & Stockholders Equity507.93558.32583.54638.50241.38252.35
Book Value Per Share2.042.352.662.760.780.89
Tangible Book Value Per Share2.042.352.662.760.780.89
Full-Time Employees---317--
Price to Book Ratio1.672.182.6221.888.185.83
Return on Assets-56.19-49.95-42.11-41.26-40.66-56.32
Return on Equity-78.80-67.42-53.11-54.97-86.51-171.41
Return on Invested Capital-14.04-14.05-5.03-9.93-37.45-31.40
Quick Ratio8.389.9911.266.472.512.56
Current Ratio8.389.9911.266.472.512.56

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-61.85-69.19-26.09-51.71-55.24-52.19
Depreciation2.292.362.312.202.292.27
Other Funds (Non Cash)9.7510.639.067.196.646.39
Funds from Operations-49.81-56.19-14.72-42.33-46.32-43.53
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-10.282.81-44.8310.200.42-4.42
Cash from Operating Activities-60.09-53.39-59.55-32.12-45.90-47.94
Capital Expenditures-0.02-0.88-0.440.01-0.25-0.31
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments-113.80-122.360.000.000.000.00
Purchase of Investments-113.80-122.360.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources3.080.000.000.000.000.00
Cash from Investing Activities-110.74-123.24-0.440.01-0.25-0.31
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.430.332.53442.6333.4111.97
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.430.332.53442.6333.4111.97
Proceedsfrom Stock Options0.000.000.00432.8530.8711.32
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities0.430.332.53442.6333.4111.97
Exchange Rate Effect-0.120.12-0.00-0.06-0.030.04
Net Change in Cash-170.52-176.18-57.47410.46-12.77-36.24
Free Cash Flow-60.10-54.27-59.99-32.11-46.16-48.26

Revenue breakdown

Pharmaceutical Preparations2024: 108.30M 2025: 42.73M
United States2024: 108.30M 2025: 42.73M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3012.49%20.6M165.3M3.30M
2026-10-1512.80%21.2M165.3M3.14M
2026-09-3011.23%18.6M165.3M3.05M
2026-09-1510.67%17.6M165.3M3.12M
2026-08-319.90%16.3M164.5M3.09M
2026-08-149.85%16.2M164.5M3.27M
2026-07-3110.11%16.4M162.3M3.36M
2026-07-1510.63%16.8M158.4M3.71M
2026-06-3013.19%20.9M158.4M3.97M
2026-06-1511.46%18.2M158.4M4.82M
2026-05-2911.70%18.5M158.4M4.67M
2026-05-1511.26%17.8M157.8M4.47M
2026-04-3010.59%16.7M157.9M4.19M
2026-04-158.46%13.3M157.7M4.16M
2026-03-318.38%13.2M157.7M4.50M
2026-03-138.51%13.4M157.7M3.39M
2026-02-278.66%13.7M157.7M6.85M
2026-02-139.95%15.2M153.3M6.77M
2026-01-3010.06%15.2M150.8M6.87M
2026-01-1510.07%15.2M150.8M6.84M

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call1.000.804.902.760.0005.000.000.969-0.0120.000
call1.501.352.501.8610.1011.000.000.954-0.0110.001
call2.000.852.000.007.4060.000.000.904-0.0170.001
call2.500.004.901.008.8532.000.000.806-0.0280.001
call3.000.201.450.856.42921.000.000.714-0.0530.002
call3.500.000.950.404.7063110.000.724-0.0790.002
call4.000.100.200.121.6099824.000.310-0.0170.002
call4.500.000.850.262.1413060.000.256-0.0210.002
call5.000.000.750.052.56947460.000.227-0.0230.002
call5.500.004.300.202.9315.000.000.208-0.0250.002
call6.000.000.050.052.8565210.000.151-0.0200.001
call7.000.000.600.072.8756500.000.084-0.0130.001
call8.000.000.950.053.2547.000.000.077-0.0140.001
call9.000.000.050.003.4040.000.000.072-0.0130.001
put1.000.001.750.005.5020.000.00-0.031-0.0120.000
put1.500.001.050.053.83910.000.00-0.046-0.0110.001
put2.000.001.100.073.30081.000.00-0.096-0.0170.001
put2.500.000.250.253.3432020.00-0.194-0.0280.001
put3.000.000.800.255.1491140.00-0.286-0.0530.002
put3.500.004.700.3512.8601478.00-0.276-0.0790.002
put4.000.504.900.7010.0869821.00-0.690-0.0170.002
put4.500.004.900.007.8880.000.00-0.744-0.0200.002
put5.000.102.401.955.9451320.00-0.773-0.0230.002
put5.500.305.000.007.7910.000.00-0.792-0.0250.002
put6.002.003.203.785.7842.000.00-0.904-0.0120.001
put7.003.004.200.006.3920.000.00-0.916-0.0130.001
put8.004.007.000.0016.6190.000.00-0.923-0.0130.001
put9.003.107.700.0014.9570.000.00-0.928-0.0140.001

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-10-27SCHEDULE 13GSEC
2026-10-27SCHEDULE 13G/ASEC
2026-10-2710-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-10-278-KCurrent report2026-10-27SEC
2026-10-14ARSAnnual report to security holders. 2025-12-31SEC
2026-10-14DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-11-12SEC
2026-10-074Statement of changes in beneficial ownership of securities2026-10-05SEC
2026-10-074Statement of changes in beneficial ownership of securities2026-10-05SEC
2026-10-074Statement of changes in beneficial ownership of securities2026-10-05SEC
2026-10-074Statement of changes in beneficial ownership of securities2026-10-05SEC
2026-10-074Statement of changes in beneficial ownership of securities2026-10-05SEC
2026-10-074Statement of changes in beneficial ownership of securities2026-10-05SEC
2026-10-074Statement of changes in beneficial ownership of securities2026-10-05SEC
2026-10-074Statement of changes in beneficial ownership of securities2026-10-05SEC
2026-08-14EFFECTEffectiveness filing by commission orderSEC
2026-08-134Statement of changes in beneficial ownership of securities2026-08-11SEC
2026-08-134Statement of changes in beneficial ownership of securities2026-08-12SEC
2026-08-134Statement of changes in beneficial ownership of securities2026-08-11SEC
2026-08-134Statement of changes in beneficial ownership of securities2026-08-11SEC
2026-08-12144Filing for proposed sale of securities under Rule 144.SEC
2026-08-11144Filing for proposed sale of securities under Rule 144.SEC
2026-08-11SCHEDULE 13D/ASEC
2026-08-1015-12GSEC
2026-08-10POS AMPost-effective amendment to a registration statement that is not immediately effective upon filingSEC
2026-08-10POSASRPost-effective amendment to an automatic shelf registration statement of Form S-3ASR or Form F-3ASRSEC
2026-08-10S-8 POSPost-effective amendment to a S-8 registration statementSEC
2026-08-10S-8 POSPost-effective amendment to a S-8 registration statementSEC
2026-08-10S-8 POSPost-effective amendment to a S-8 registration statementSEC
2026-08-10S-8 POSPost-effective amendment to a S-8 registration statementSEC
2026-08-10S-8 POSPost-effective amendment to a S-8 registration statementSEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-0800135.07K4
2026-070000
2026-060000
2026-050000
2026-040000
2026-0354.62M300
2026-0200757.55K5
2026-0100150.26K1
2025-1227.93M115.03M9
2025-116.69K1109.42K1

Institutional holders

Manager% owned
RA CAPITAL MANAGEMENT, L.P.14.02%
BlackRock, Inc.9.98%
GSK plc9.26%
MAVERICK CAPITAL LTD5.34%
DRIEHAUS CAPITAL MANAGEMENT LLC2.83%
PRIMECAP MANAGEMENT CO/CA/2.78%
683 Capital Management, LLC2.57%
STATE STREET CORP2.52%
READYSTATE ASSET MANAGEMENT LP2.46%
M28 Capital Management LP2.38%

Funds

Fund% owned
PRIMECAP Odyssey Aggressive Growth Fund2.14%
Fidelity Growth Company Fund0.84%
BlackRock Advantage Small Cap Core Fund0.77%
VANGUARD RUSSELL 2000 INDEX FUND0.40%
Driehaus Small Cap Growth Fund0.39%
Schwab U.S. Small-Cap ETF0.36%
Federated Hermes MDT Small Cap Core Fund0.33%
Fidelity Extended Market Index Fund0.30%
Fidelity Growth Company K6 Fund0.24%
Federated Hermes Kaufmann Fund0.22%

OakChart. WVE. Cached 15 minutes.